Island Pharmaceuticals 12 Month Report

Island Pharmaceuticals (ILA), a biotech company focused on developing ISLA-101 for mosquito-borne diseases, has begun a Phase II study of the drug targeting Dengue fever. Initial results from the first cohort are expected by December 2024, with complete results anticipated in 2025. Stock of ILA is expected to increase to the range of A$0.31 to A$0.41.

Learn more